2855 GAZELLE COURT, CARLSBAD, CA
Proven to deliver significant and robust triglyceride reductions –– Only treatment for sHTG indicated to reduce the risk of acute pancreatitis –– first independent commercial launch in a prevalent condition –– to host webcast today at 3:30 p.m. ET
News
Announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Partner announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Reports First Quarter 2026 Financial Results and Highlights Progress on Key Programs®- Olezarsen sNDA Accepted by the FDA for Priority Review; sHTG Launch Preparations on Track –– Increasing Annual TRYNGOLZA Peak Net Sales Guidance to >$3B for sHTG –- Zilganersen NDA for Alexander Disease Accepted for Priority Review, Paving Way for First Independent Launch from Leading Neuro
Annual Report to Security Holders
New Data from Pivotal Study of Zilganersen in Alexander Disease (AxD) at AAN 2026 Annual Meeting
Changes to Board of Directors– Lynne Parshall and Joseph Wender to Retire at End of Term in June 2026 and Peter Reikes to Join Board
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Notice of Proposed Sale of Securities